enGene Holdingsの空売り状況は、投資家がenGene Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

enGene Holdings (NASDAQ:ENGN) 株価情報, 空売り情報

iShares Industrial Bond ETF

enGene Holdings

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

enGene Holdings Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcac1f558000155e857/atif-malik">Citigroup analyst Atif Malik</a> initiated coverage on Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy rating and announced a price target of $120. Astera Labs shares closed at $86.45 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Catherine Novack initiated coverage on Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy rating and announced a price target of $130. Korro Bio shares closed at $47.56 on Friday. See how other analysts view this stock.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59411d2985b07a0001615cae/ruplu-bhattacharya">B of A Securities analyst Ruplu Bhattacharya </a>initiated coverage on Ingram Micro Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announced a price target of $30. Ingram Micro shares closed at $22.75 on Friday. See how other analysts view this stock.</li>
<li>RBC Capital analyst Victoria McCulloch initiated coverage on TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with an Outperform rating and announced a price target of $37. TechnipFMC shares closed at $28.18 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform rating and announced a price target of $18. enGene shares closed at $7.63 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FTI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-1024x558.png" alt="" class="wp-image-652827" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181.png 1222w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALAB

ENGN

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

JMP Securities analyst Silvan Tuerkcan initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform rating and announces Price Target of $18.

Price Target

JMP Securities Initiates Coverage On enGene Holdings with Market Outperform Rating, Announces Price Target of $18

enGene Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) shares are trading higher by 7.2% to $9.54 during Friday&#8217;s session. The company announced it generated approximately $60 million in proceeds from a <a href="https://www.benzinga.com/pressreleases/24/10/b41542460/engene-announces-60-million-private-placement-financing">private placement</a>.
enGene announced a private placement to sell 6,758,311 common shares at $8.90 each, aiming to raise approximately $60 million before expenses. This financing is set to close on October 29, pending standard conditions, and involves participation from both new and existing investors, such as Deep Track Capital and Venrock Healthcare Capital Partners. 
The company says funds will support the development of enGene&#8217;s lead product, detalimogene voraplasmid, pre-commercial activities, potential expansion of the DDX platform, and general corporate needs.
Combined with existing cash, these proceeds are expected to sustain operations through 2027.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41544385/microstrategy-pushes-higher-as-blackrock-buys-in-but-peter-schiff-sees-a-crash-ahead">MicroStrategy Pushes Higher As BlackRock Buys In, But Peter Schiff Sees A Crash Ahead</a>
<h2 class="wp-block-heading">How To Buy ENGN Stock</h2>
By now you're likely curious about how to participate in the market for enGene Holdings &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of enGene Holdings, which is trading at $9.75 as of publishing time, $100 would buy you 10.26 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ENGN has a 52-week high of $43.00 and a 52-week low of $4.42.

Why enGene Holdings Stock Is Trading Higher

WIIM

EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.

enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90. The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any offering-related expenses.
The financing included participation from new and existing investors, including Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital and Venrock Healthcare Capital Partners.

Offerings

enGene Announces That It Has Agreed To Sell 6,758,311 Of Its Common Shares At A Price Per Share Of $8.90; Anticipates The Gross Proceeds From The Private Placement To Be ~$60M

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 150 points on Thursday.
Shares of International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) fell sharply in today's pre-market trading session following a <a href="https://www.benzinga.com/news/earnings/24/10/41502267/ibm-q3-earnings-software-revenue-jumps-10-on-great-momentum-in-ai-but-consulting-revenue-comes-in-f">third-quarter revenue miss</a>.
IBM reported third-quarter revenue of $14.968 billion, missing the consensus estimate of $15.07 billion, according to Benzinga Pro.
IBM shares tumbled 5% to $221.28 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) declined 16.3% to $235.13 in pre-market trading following worse-than-expected third-quarter financial results.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) shares declined 12.6% to $6.97 in pre-market trading following weak quarterly sales.</li>
<li>Beyond, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NASDAQ">BYON</a>) shares dipped 12% to $8.38 in pre-market trading after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares declined 9.9% to $72.00 in pre-market trading following worse-than-expected third-quarter revenues.</li>
<li>Spirit Airlines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NASDAQ">SAVE</a>) shares fell 5.2% to $2.92 in pre-market trading after jumping 46% on Wednesday.</li>
<li>enGene Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) shares fell 4.1% to $8.96 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41508724/tesla-dow-and-3-stocks-to-watch-heading-into-thursday">Tesla, Dow And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Movers

BYON

CARR

ICLR

SAVE

IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

EnGene shares are trading lower. The company announced preliminary data from its LEGEND study of Detalimogene Voraplasmid (EG-70).

Biotech

Health Care

General

enGene Announced Preliminary Data From LEGEND Study Of Detalimogene Voraplasmid (EG-70) In Bacillus Calmette-guérin-unresponsive, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ, Showing Complete Response Rate At Any Time Of 71%

Oppenheimer analyst Leland Gershell reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Outperform and maintains $30 price target.

Reiteration

Oppenheimer Reiterates Outperform on enGene Holdings, Maintains $30 Price Target

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Overweight and maintains $40 price target.

Morgan Stanley Maintains Overweight on enGene Holdings, Maintains $40 Price Target

Guidance

enGene Remains On Track To Report Preliminary LEGEND Data In September 2024; Cash And Equivalents Of $257.7M Provide Runway Into 2027

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent.

Earnings

Earnings Beats

enGene Holdings Q3 2024 GAAP EPS $(0.32) Beats $(0.35) Estimate

Oppenheimer analyst Leland Gershell initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Outperform rating and announces Price Target of $30.

Oppenheimer Initiates Coverage On enGene Holdings with Outperform Rating, Announces Price Target of $30

<ul>
<li>Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director</li>
<li>Company also announces Dr. Raj Pruthi&#39;s promotion to Chief Medical Officer</li>
</ul>

enGene Names Ron Cooper As Chief Executive Officer, Effective July 22, 2024

EnGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) shares are trading lower Friday after the company, reported its <a href="https://www.benzinga.com/pressreleases/24/06/b39329343/engene-reports-second-quarter-2024-financial-results-and-provides-a-business-update">financial results for the second quarter.</a>
What To Know: EnGene Holdings announced a net loss of $15.0 million, or $0.38 per share, compared to a loss of $6.5 million, or $9.30 per share, for the same period in 2023, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. This increase in net loss is primarily due to higher operating expenses, which rose from $4.7 million to $17.3 million year-over-year, driven by increased research and development costs and administrative expenses as the company scales its operations.
What Else: In addition to financial updates, EnGene highlighted strategic developments, including the planned expansion of its pivotal LEGEND study to include high-risk, BCG-unresponsive papillary-only NMIBC patients. Interim data from this cohort is expected by the end of September 2024, with a Biologics License Application (BLA) for EG-70 projected for mid-2026.
Related Link: <a href="https://www.benzinga.com/pressreleases/24/06/b39329343/engene-reports-second-quarter-2024-financial-results-and-provides-a-business-update">enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update</a>
EnGene has also made key leadership hires, including Dr. Raj Pruthi as SVP of Urologic Oncology and Clinical Development, to bolster their clinical efforts. Despite the financial challenges, enGene remains focused on advancing EG-70 and exploring additional applications within bladder cancer.
Price Action: EnGene Holdings shares were down by 11.6% at $8.84 according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14134648/ENGN-1024x546.png" alt="" class="wp-image-389543" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14134648/ENGN-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14134648/ENGN-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14134648/ENGN-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/14134648/ENGN.png 1387w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39338356/why-is-nano-nuclear-energy-stock-soaring-on-friday">Why Is NANO Nuclear Energy Stock Soaring On Friday?</a>
Photo Via Shutterstock.

Why Are EnGene Holdings Shares Trading Lower Friday?

EnGene Holdings shares are trading lower after the company reported Q2 financial results.

For the three months ended April 30, 2024, net loss attributable to common shareholders was approximately&nbsp;$15.0 million, or&nbsp;$0.38&nbsp;per share, compared to approximately&nbsp;$6.5 million, or&nbsp;$9.30&nbsp;per share, for the same period for the three months ended April 30, 2023. The increase in net loss is mainly attributed to the increase in operating expenses partially offset by net interest income earned during the period.

enGene Reports Q2 EPS Of $(0.38) Loss, Company Exits Quarter With Cash & Equivalents Worth $264.8M

Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations
BOSTON and MONTREAL, May 2, 2024 /CNW/ -&nbsp;enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.
The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)," will be given by Dr. Gordon Brown, Director of the Center for Advanced Therapeutics and Urologic Oncology, Summit Health-South, at 10:30 a.m. CT on Friday, May 3rd during the Paradigm-shifting, Practice-changing Clinical Trials in Urology Plenary Session. The complete dataset from the 12-month follow-up of all patients in the Phase 1 portion of LEGEND will be reported at a future meeting or within a peer-reviewed publication.
"I am pleased to present a detailed overview of EG-70 and the pivotal Phase 1/2 LEGEND study. EG-70 is designed to be a practice-changing product that does not require a change in practice for urologists, offering attributes that render it practical for use in community-based and high-volume clinics." said Dr. Brown.
Dr. Richard Bryce, enGene's Chief Medical Officer, added: "The promising initial efficacy and safety data from LEGEND's Phase 1 cohort in high-risk, BCG-unresponsive NMIBC patients with CIS, combined with its ease of handling, simplicity of administration, minimal storage requirements, and lack of post-procedural patient restrictions, demonstrate EG-70's potential to unlock the power of genetic medicine for any and all urologists."
"EG-70 was rationally designed to be easy to use and meet the needs of patients and urologists alike. As a non-viral, non-infectious, locally delivered genetic medicine, EG-70 is designed to synergistically activate both the innate and adaptive immune responses, be easily reconstituted in water, and require only a short procedural time," said Jason Hanson, Chief Executive Officer of enGene. "Within the subgroup of patients in LEGEND's Phase 1 who received our optimized Phase 2 dose, we saw complete response rates of 70% and 60% at three months and six months, respectively, which speak to EG-70's potential to drive durable remissions. The encouraging safety data from the Phase 1 study also suggest that this efficacy was achieved without significant impairment to the patients' quality of life. We look forward to providing additional updates on the broader EG-70 program as we look to expand its potential use across bladder cancer."

enGene To Present Details Of Its Pivotal Phase 1/2 LEGEND Study Of EG-70 In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ At The American Urology Association 2024 Annual Meeting

Wells Fargo analyst Yanan Zhu initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Overweight rating and announces Price Target of $30.

Wells Fargo Initiates Coverage On enGene Holdings with Overweight Rating, Announces Price Target of $30

Guggenheim analyst Manuel Navas initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $34.

Guggenheim Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $34

Wells Fargo analyst Yanan Zhu maintained a Buy rating on enGene Holdings (ENGN – Research Report) on September 26 and set a price target of $30.00....

Buy Rating Affirmed on enGene Holdings Amidst Promising Efficacy Data and Strategic Protocol Amendments

Analysts have been eager to weigh in on the Real Estate sector with new ratings on enGene Holdings (ENGN – Research Report), CoStar Group (CSGP – R...

Analysts' Opinions Are Mixed on These Real Estate Stocks: enGene Holdings (ENGN), CoStar Group (CSGP) and Umh (UMH)

enGene (ENGN) announced the appointment of Joan Connolly as CTO and member of the corporate leadership team. In addition, enGene co-founder and for...

enGene CTO Anthony Cheung transitions to CSO, Joan Connolly to succeed

enGene Holdings ( ($ENGN) ) has issued an update. enGene Holdings Inc. has announced significant changes to its executive team on October 21, 2024,...

enGene Holdings Announces Key Executive Appointments

enGene announces $60M private placement financing

enGene Holdings ( ($ENGN) ) has provided an announcement. enGene Holdings Inc. plans a $60 million private placement of 6.7 million common shares a...

enGene Holdings Secures $60 Million for Genetic Medicines

enGene Holdings files for mixed shelf offering

17:06 EST enGene (ENGN) files to sell 46.98M common shares, 6.29M warrants for holders Published first on TheFly – the ultimate source for real-tim...

enGene files to sell 46.98M common shares, 6.29M warrants for holders

16:55 EST enGene (ENGN) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

enGene files $300M mixed securities shelf

JMP Securities analyst Silvan Tuerkcan initiated coverage of enGene (ENGN) with an Outperform rating and $18 price target enGene is a clinical-stag...

Comments

enGene Holdings

空売り

enGene Holdings (NASDAQ:ENGN) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル